ArticleBlood2008
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Detection of the full-length transcript variant for neurokinin-1 receptor in human whole blood associated with enhanced reinforcement of clot by substance-P.Journal of thrombosis and thrombolysis · 2012Trial
- Methylation in the TAC1 Gene Promoter Is Associated with the Transition from Acute Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension.International journal of molecular sciences · 2026Article
- Evidence for control of cerebral neurovascular function by circulating platelets in healthy older adults.The Journal of physiology · 2025Article
- Review
- Differential Proteoglycan Expression in Atherosclerosis Alters Platelet Adhesion and Activation.International journal of molecular sciences · 2024Article
- Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.Journal of clinical medicine · 2023Article
- The brain-derived neurotrophic factor prompts platelet aggregation and secretion.Blood advances · 2021Article
- Elevated serum substance P during simian varicella virus infection in rhesus macaques: implications for chronic inflammation and adverse cerebrovascular events.Journal of neurovirology · 2020Article
- The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?Cancers · 2020Review
- The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.European journal of histochemistry : EJH · 2020Article
- Serum Levels of Substance P and Mortality in Patients with a Severe Acute Ischemic Stroke.International journal of molecular sciences · 2016Article
- Morphology and neurochemistry of rabbit iris innervation.Experimental eye research · 2015Article
- The role of substance p in ischaemic brain injury.Brain sciences · 2013Article
- Article
- Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor.Journal of neuroimmunology · 2012Article
- Platelet endothelial cell adhesion molecule-1 regulates collagen-stimulated platelet function by modulating the association of phosphatidylinositol 3-kinase with Grb-2-associated binding protein-1 and linker for activation of T cells.Journal of thrombosis and haemostasis : JTH · 2010Article
- Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation.Journal of thrombosis and haemostasis : JTH · 2010Article
- Neurokinin B and pre-eclampsia: a decade of discovery.Reproductive biology and endocrinology : RB&E · 2010Review
- Platelets and cardiac arrhythmia.Frontiers in physiology · 2010Article
- PECAM-1 expression and activity negatively regulate multiple platelet signaling pathways.FEBS letters · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Platelets play an important role in hemostasis, with inappropriate platelet activation being a major contributor to debilitating and often fatal thrombosis by causing myocardial infarction and stroke. Although current antithrombotic treatment is generally well tolerated and effective, many patients still experience cardiovascular problems, which may reflect the existence of alternative underlying regulatory mechanisms in platelets to those targeted by existing drugs. In this study, we define a role for peripherally distributed members of the tachykinin family of peptides, namely substance P and the newly discovered endokinins A and B that are present in platelets, in the activation of platelet function and thrombus formation. We have reported previously that the preferred pharmacologically characterized receptor for these peptides, the NK1 receptor, is present on platelets. Inhibition or deficiency of the NK1 receptor, or SP agonist activity, resulted in substantially reduced thrombus formation in vitro under arterial flow conditions, increased bleeding time in mice, and a decrease in experimentally induced thromboembolism. Inhibition of the NK1 receptor may therefore provide benefit in patients vulnerable to thrombosis and may offer an alternative therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.